Translational Research Office (TRO)
UCL’s Translational Research Office (TRO) builds on
an increasingly vibrant translational culture across the School of Life and
Medical Sciences (SLMS) and the wider university community by providing
integrated support for translational research, industrial partnerships and drug
Through working closely with a broad spectrum of investigators, industry partners and external funding bodies, the TRO facilitates the translation of UCL’s emerging research into therapies, techniques and medical products with therapeutic value. The TRO aims to provide practical help and expertise to investigators wishing to explore the translational pathway for their idea / project and to negotiate the hurdles and barriers that are inevitably encountered during the progression from idea to health benefit.
The TRO also develops strategies for engaging effectively with global and national companies and institutions and responds to corporate and academic needs through networking opportunities, tailored partnerships, projects, and brand-building initiatives.
There are three core groups each offering specialised support and advice:
The Translational Research Group (TRG)
works with researchers to develop translational plans and to secure funding
from multiple sources including MRC, Wellcome Trust, National Institute for
Health Research (NIHR), Technology Strategy Board (TSB) and various charities.
Translational Research Managers have been pivotal in securing approximately
£50M translational grant funding for UCL projects, and are currently managing a
growing portfolio of over 30 major translational projects. Activities include
assisting funding applications, advising on critical path activities, managing
funded projects and securing follow-on funding.
The Drug Discovery Group (DDG) provides theoretical and practical expertise to support the progression of selected UCL projects. Activities include the assessment of target tractability; development of project, medicinal chemistry, and screening strategies; compound design and synthesis; hit discovery and validation; and hit to lead optimisation. The DDG is based in established labs in the UCL School of Pharmacy and is part of the wider UCL Drug Discovery Cluster. The Drug Discovery group also hosts the Innovative Therapeutics Postdoctoral Training Programme (ITPTP).
Business Intelligence & Innovation
The Business Intelligence and Innovation Group (BI&IG) provides strategic support to Faculties across UCL, to enhance the translation of Biomedical Research across all therapeutic modalities, through collaboration with stakeholders in the Healthcare sector. Our activities include brokering interactions for UCL academics with industry, to identify and create new collaboration opportunities and assist academics in forming bespoke partnerships. We support UCL’s translational research strategy through mapping internal research capabilities, building multidisciplinary translational research communities and aligning those internal strengths with unmet market needs. Therapeutic Innovation Networks such as Cell, Gene &Regenerative Medicine, Small Molecules, Biologics, Devices and Diagnostics are key areas of focus supported by the BI&IG.